UK-based medical technology company Smith+Nephew has obtained approval from National Medical Products Administration (NMPA) to launch its REDAPT System for revision total hip arthroplasty (rTHA) in China.
The REDAPT System is designed to help surgeons to overcome the challenges of revision hip arthroplasty, including the fixation in various bone types, the achievement of joint stability, predictable stem position and surgical efficiency.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It helps to lower the re-revision rate of rTHAs by reducing the frequency of implant movement, which is considered a major cause for early failure of total hip arthroplasty.
Furthermore, the REDAPT System has acetabular components that are among the first 3D-printed, imported, acetabular products approved for use in China.
Smith+Nephew Greater China managing director Ala Ahram said: “China has seen rapid growth in primary hip procedures over the past 15-20 years and as such, there is a need for technologies addressing the clinical needs for revision hip arthroplasty.
“Introducing the REDAPT System in China will have a profoundly positive clinical impact to our surgeon customers.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRevision total hip arthroplasty procedure volume is expected to increase globally as younger, more active patients outlive their original implants.
The approval of REDAPT System expands Smith+Nephew’s portfolio of both primary and revision hip arthroplasty products currently available in China. The system is expected to be commercially available in China later this year.
In July, Smith+Nephew launched a handheld robotics platform for unicompartmental knee arthroplasty and total knee arthroplasty.
In January, the company acquired Tusker Medical for an undisclosed amount as part of its strategy to invest in advanced technologies to meet medical requirements.
